DBV Technologies (DBV Technologies) Forward PE Ratio : 0.00 (As of May. 22, 2024)

View and export this data going back to 2014. Start your Free Trial

What is DBV Technologies Forward PE Ratio?

DBV Technologies's Forward PE Ratio for today is 0.00.

DBV Technologies's PE Ratio without NRI for today is 0.00.

DBV Technologies's PE Ratio for today is 0.00.

DBV Technologies Forward PE Ratio Historical Data

The historical data trend for DBV Technologies's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Forward PE Ratio Chart

DBV Technologies Annual Data

Trend

Forward PE Ratio

DBV Technologies Quarterly Data

Forward PE Ratio

Competitive Comparison of DBV Technologies's Forward PE Ratio

For the Biotechnology subindustry, DBV Technologies's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DBV Technologies's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Forward PE Ratio falls into.

DBV Technologies Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

DBV Technologies (NAS:DBVT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

DBV Technologies Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of DBV Technologies's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

DBV Technologies (DBV Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (NAS:DBVT) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

0QAJ:UK DBV:France DBV:Germany

Address

177-181 avenue Pierre Brossolette, Montrouge, FRA, 92120

Website

http://www.dbvtechnologies.com

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Executives

Pharis Mohideen	officer: Chief Medical Officer	C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Virginie Boucinha	officer: Chief Financial Officer	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Timothy E Morris	director	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Daniel B Soland	director	4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Daniele Guyot-caparros	director	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Madduri Ravin Rao	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746
Adora Ndu	director	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Michael Goller	director	C/O BAKER BROTHERS INVESTMENTS, 667 MADISON AVENUE, 21ST FLOOR, NEW YORK NY 10065
Daniel Tasse	director, officer: Chief Executive Officer	C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809